Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total stock-based compensation expense	$ 4,764	$ 3,990	$ 14,583	$ 10,629
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	3,571	2,772	11,251	6,156
Cost Of Revenue [Member]
Total stock-based compensation expense	9		9
Sales And Marketing Expenses [Member]
Total stock-based compensation expense	643	327	1,859	814
Research and Development Expense [Member]
Total stock-based compensation expense	258	310	699	727
Lucid Diagnostics Inc. 2018 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	9		9
Lucid Diagnostics Inc. 2018 Equity Plan [Member] | Sales And Marketing Expenses [Member]
Total stock-based compensation expense	253		733
Lucid Diagnostics Inc. 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	2,990	2,695	9,504	5,988
Lucid Diagnostics Inc. 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	28	21	125	57
PAVmed Inc. 2014 Equity Plan [Member] | Sales And Marketing Expenses [Member]
Total stock-based compensation expense	161		497
PAVmed Inc. 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	78		224
PAVmed Inc. 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 52	$ 56	$ 159	$ 111